Degludec outperforms glargine in curbing nocturnal hypoglycemia

05/6/2013 | Healio

Type 1 diabetes patients who received high-dose insulin degludec once daily showed lower rates of nocturnal hypoglycemia than their counterparts who took insulin glargine, a study showed. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA